Repository logo
 
Publication

IgG Antibody responses to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Their effective potential for disease diagnosis and pathological antigenic mimicry

dc.contributor.authorFonseca, André
dc.contributor.authorSzysz, Mateusz
dc.contributor.authorLy, Hoang Thien
dc.contributor.authorCordeiro, Clara
dc.contributor.authorSepúlveda, Nuno
dc.date.accessioned2024-01-31T10:41:20Z
dc.date.available2024-01-31T10:41:20Z
dc.date.issued2024-01-15
dc.date.updated2024-01-26T14:10:47Z
dc.description.abstractThe diagnosis and pathology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remain under debate. However, there is a growing body of evidence for an autoimmune component in ME/CFS caused by the Epstein-Barr virus (EBV) and other viral infections. Materials and Methods: In this work, we analyzed a large public dataset on the IgG antibodies to 3054 EBV peptides to understand whether these immune responses could help diagnose patients and trigger pathological autoimmunity; we used healthy controls (HCs) as a comparator cohort. Subsequently, we aimed at predicting the disease status of the study participants using a super learner algorithm targeting an accuracy of 85% when splitting data into train and test datasets. Results: When we compared the data of all ME/CFS patients or the data of a subgroup of those patients with non-infectious or unknown disease triggers to the data of the HC, we could not find an antibody-based classifier that would meet the desired accuracy in the test dataset. However, we could identify a 26-antibody classifier that could distinguish ME/CFS patients with an infectious disease trigger from the HCs with 100% and 90% accuracies in the train and test sets, respectively. We finally performed a bioinformatic analysis of the EBV peptides associated with these 26 antibodies. We found no correlation between the importance metric of the selected antibodies in the classifier and the maximal sequence homology between human proteins and each EBV peptide recognized by these antibodies. Conclusions: In conclusion, these 26 antibodies against EBV have an effective potential for disease diagnosis in a subset of patients. However, the peptides associated with these antibodies are less likely to induce autoimmune B-cell responses that could explain the pathogenesis of ME/CFS.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationMedicina 60 (1): 161 (2024)pt_PT
dc.identifier.doi10.3390/medicina60010161pt_PT
dc.identifier.eissn1648-9144
dc.identifier.urihttp://hdl.handle.net/10400.1/20326
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationAnalysis of high-throughput antibody data for better understanding of immunogenetics and epidemiology of malaria
dc.relationCentre of Statistics and its Applications
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBiomarker discoverypt_PT
dc.subjectDisease pathogenesispt_PT
dc.subjectAutoimmunitypt_PT
dc.subjectAntigenic mimicrypt_PT
dc.subjectMachine learningpt_PT
dc.titleIgG Antibody responses to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Their effective potential for disease diagnosis and pathological antigenic mimicrypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleAnalysis of high-throughput antibody data for better understanding of immunogenetics and epidemiology of malaria
oaire.awardTitleCentre of Statistics and its Applications
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/OE/SFRH%2FBD%2F147629%2F2019/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00006%2F2020/PT
oaire.citation.issue1pt_PT
oaire.citation.startPage161pt_PT
oaire.citation.titleMedicinapt_PT
oaire.citation.volume60pt_PT
oaire.fundingStreamOE
oaire.fundingStream6817 - DCRRNI ID
person.familyNameFonseca
person.familyNameHenrique Cordeiro
person.givenNameAndré
person.givenNameClara Maria
person.identifier.ciencia-idC71E-21A1-E882
person.identifier.orcid0000-0001-8249-0354
person.identifier.orcid0000-0002-1026-6078
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationf87bcc49-7faa-47a8-959b-c9be8ee07d19
relation.isAuthorOfPublication7e0bbaff-c584-461a-84e2-54f2a6c15876
relation.isAuthorOfPublication.latestForDiscovery7e0bbaff-c584-461a-84e2-54f2a6c15876
relation.isProjectOfPublication7187315f-98e6-4671-9731-fc2bea229681
relation.isProjectOfPublication100e6d17-2f76-4282-b864-d0f887b34243
relation.isProjectOfPublication.latestForDiscovery100e6d17-2f76-4282-b864-d0f887b34243

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
medicina-60-00161-v4.pdf
Size:
3.29 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description: